| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
143,520,000 |
| Market
Cap: |
63.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4425 - $0.4425 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,431,765 |
4,794,057 |
4,794,057 |
4,794,057 |
| Total Buy Value |
$20,571,167 |
$89,496,413 |
$89,496,413 |
$89,496,413 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
2 |
6 |
6 |
6 |
| Total Shares Sold |
0 |
6,161,499 |
6,722,029 |
6,722,029 |
| Total Sell Value |
$0 |
$121,266,413 |
$128,353,600 |
$128,353,600 |
| Total People Sold |
0 |
6 |
7 |
7 |
| Total Sell Transactions |
0 |
24 |
32 |
32 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Duker Jay S. |
Chief Operating Officer |
• – – |
2022-11-01 |
4 |
D |
$5.42 |
$24,276 |
D/D |
(4,479) |
21,402 |
|
- |
|
| Duker Jay S. |
Chief Operating Officer |
• – – |
2022-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,258 |
25,881 |
|
- |
|
| Pine Michael Craig |
Chief Corp Dev.&Strat. Officer |
• – – |
2022-03-14 |
4 |
B |
$12.21 |
$12,210 |
D/D |
1,000 |
1,000 |
0.01 |
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2022-02-28 |
4 |
D |
$9.95 |
$12,875 |
D/D |
(1,294) |
18,651 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,105 |
19,945 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,466 |
150,281 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2022-02-28 |
4 |
D |
$9.95 |
$11,244 |
D/D |
(1,130) |
15,599 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,105 |
16,729 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2022-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,717 |
137,815 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2022-02-09 |
4 |
D |
$10.13 |
$14,921 |
D/D |
(1,473) |
12,624 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,966 |
14,097 |
|
- |
|
| Guyer David R |
|
– • – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
4,400 |
|
- |
|
| Dicicco Wendy F |
|
– • – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
4,400 |
|
- |
|
| Landis John B. |
|
– • – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
8,400 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2022-02-09 |
4 |
D |
$10.13 |
$17,434 |
D/D |
(1,721) |
15,840 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,966 |
17,561 |
|
- |
|
| Ando Goran |
|
– • – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,750 |
4,900 |
|
- |
|
| Elston George |
Chief Financial Officer |
• – – |
2022-02-09 |
4 |
D |
$10.13 |
$17,434 |
D/D |
(1,721) |
9,602 |
|
- |
|
| Elston George |
Chief Financial Officer |
• – – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,966 |
11,323 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,533 |
124,098 |
|
- |
|
| Duker Jay S. |
Chief Operating Officer |
• – – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,966 |
10,623 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2021-11-15 |
4 |
AS |
$20.15 |
$201,480 |
D/D |
(10,000) |
103,546 |
|
-100% |
|
| Duker Jay S. |
Chief Operating Officer |
• – – |
2021-11-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,657 |
|
-100% |
|
| Godshall Douglas Evan |
|
– • – |
2021-06-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
8,016 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2021-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,500 |
113,546 |
|
- |
|
268 Records found
|
|
Page 5 of 11 |
|
|
